Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

REM sleep behaviour disorder

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise dream-enactment behaviour, confirm REM sleep without atonia, prevent injury, exclude mimics and medicines, and provide proportionate counselling and follow-up for associated synucleinopathy risk.

  • REM sleep behaviour disorder causes vocalisation and complex movement that corresponds to vivid dreams because the normal skeletal-muscle atonia of REM sleep is lost.
  • Events are often reported by a bed partner and may include shouting, punching, kicking, leaping or falling from bed, with rapid alertness and dream recall when awakened.
  • Diagnosis requires a compatible history plus video polysomnographic evidence of REM sleep without atonia, with another sleep, neurological or substance cause excluded.
  • Obstructive sleep apnoea can provoke vigorous arousals that mimic RBD, while nocturnal epilepsy, NREM parasomnia, periodic movements, PTSD and nocturnal panic need different management.
  • Ask about antidepressants, beta blockers, alcohol and sedative withdrawal, but do not stop an antidepressant abruptly; weigh psychiatric stability and symptom timing with the prescriber.
  • Immediate management is environmental safety: remove weapons and sharp furniture, pad the floor, lower or separate the bed when necessary and protect the bed partner without restraining the sleeper.
  • Clonazepam and melatonin are commonly used by specialists, but evidence is limited and selection must account for falls, cognition, obstructive sleep apnoea, respiratory depression and daytime sedation.
  • Idiopathic or isolated RBD is strongly associated with later Parkinson disease, dementia with Lewy bodies or multiple-system atrophy, but individual timing is uncertain and counselling should avoid deterministic prediction.

Key red flags

Strangulation, weapon use, major falls, head injury or risk to a bed partner requires immediate separation and environmental safety before diagnostic testing is complete.

Events with prolonged unresponsiveness, stereotyped tonic posturing, tongue injury or post-ictal confusion require assessment for nocturnal epilepsy.

Loud snoring, witnessed apnoea, cyanosis or marked daytime sleepiness suggests untreated obstructive sleep apnoea and increases sedative treatment risk.

Rapid cognitive decline, recurrent visual hallucinations, parkinsonism or severe autonomic failure requires expedited neurological assessment for established neurodegenerative disease.

Daytime falls, confusion or respiratory worsening after clonazepam or another sedative requires prompt dose and treatment review.

Investigation priorities

01
Bed-partner history and event videoFirst step

Characterise timing, vocalisation, movement, dream recall, responsiveness, breathing and injury from a witness perspective.

Management branches

SAFEInjury prevention tonight

Dream enactment has caused or nearly caused harm before specialist diagnosis.

  1. Remove weapons, glass, sharp furniture and unstable bedside objects and pad nearby surfaces or place a mattress low to the floor.
  2. Use separate sleeping temporarily when the partner is at risk and avoid physical restraint, which can intensify injury during an event.
  3. Reduce sleep deprivation and alcohol and review sedatives, while not stopping antidepressants or dependence-forming medicines abruptly.
  4. Arrange sleep-service assessment and seek urgent care for head injury, breathing compromise or episodes suggesting seizure.

Key medicines

Modified-release melatoninUse an off-label or licensed-formulation dose selected by the sleep specialist, commonly starting low in the evening and titrating gradually to nocturnal behaviour and morning alertness.Product bioavailability varies, evidence is limited, and daytime drowsiness, headache and interactions can occur; prescribe a consistent regulated preparation.
ClonazepamA specialist may start 0.25–0.5 mg orally at bedtime and cautiously titrate only if dangerous behaviours persist and tolerability remains acceptable.Falls, cognitive impairment, dependence, daytime sedation and worsening obstructive sleep apnoea or respiratory disease are important; avoid alcohol and opioids and do not stop abruptly.
Open full textbook →Answer 2 questions
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG97 dementia recommendationsREM sleep behaviour disorder as a Lewy body dementia feature and diagnostic context.
  • NICE NG71 Parkinson disease recommendationsSleep disturbance and specialist neurological review in Parkinson disease.
  • BNF clonazepam monographUK dosing, respiratory, falls and dependence cautions.
  • BNF melatonin monographUK formulations, adverse effects and interactions.
  • DVLA neurological fitness guidanceDriving standards when neurological disease or daytime sleepiness affects safety.
  • International RBD diagnostic proceduresPrimary expert consensus on video-polysomnographic diagnosis.
  • AASM clinical practice guideline for RBDPrimary guideline supporting injury prevention and treatment choices; applied with UK formulary governance.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draft
Clinical stateAwaiting review
JurisdictionUnited Kingdom